Akari Therapeutics, Plc Form 8-K Filing

On May 20, 2026, Akari Therapeutics, Plc entered into a securities purchase agreement for a private placement offering. The company agreed to sell an aggregate of 1,470,588 unregistered American Depository Shares (ADSs), each representing 80,000 ordinary shares, or pre-funded warrants in lieu thereof. These were offered alongside Series H, I, and J warrants to purchase ADSs, collectively forming "Units." The purchase price for a Unit with an ADS was $3.74, and for a Unit with a pre-funded warrant, it was $3.739. The offering is expected to gross approximately $5.5 million before fees, with net proceeds intended for working capital and general corporate purposes. The company paid Paulson Investment Company, LLC as placement agent a 2% fee and agreed to issue them 117,647 ADSs. The issuance of warrants and placement agent ADSs is subject to shareholder approval. The Warrants will have an exercise price of $3.74 per ADS and will be exercisable immediately after shareholder approval. The company is obligated to file a resale registration statement within thirty days following the Third Closing Date. The offering was made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, with purchasers represented as accredited investors. The offering is structured in three tranches, expected to close on May 27, June 15, and July 15, 2026.